West Pharmaceutical Services, Inc. (NYSE:WST) is included among the 14 Best Dividend Growth Stocks to Buy and Hold in 2026.
KeyBanc sees limited risk to oral weight loss drugs through 2030, even with the potential approval of an oral version of Wegovy. In a research note, the firm said oral GLP-1 adoption is likely to stay capped in both the near and longer term, despite new products entering the market. KeyBanc estimates the oral version of Wegovy would add only about 200 basis points to total GLP-1 market share by 2030. The firm also believes GLP-1 suppliers are taking a cautious view on market penetration. West Pharmaceutical Services, Inc. (NYSE:WST) and Stevanato Group have both pointed to assumptions that oral drugs could eventually account for 30% of the overall GLP-1 market. KeyBanc is more conservative and expects injectable formats to remain the primary growth driver as next-generation GLP-1s roll out. Under that scenario, both suppliers should continue to see volume ramp.
Earlier in October, West Pharmaceutical Services, Inc. (NYSE:WST) raised its full-year profit forecast after reporting better-than-expected third-quarter results. The improvement was tied to strong demand for components used in GLP-1 weight-loss and diabetes drugs.
The drug components business now represents 47% of total revenue. During the quarter, demand picked up as drugmakers increased orders for packaging and delivery components that are critical throughout the injectable production process.
West Pharmaceutical Services, Inc. (NYSE:WST) supplies essential medical components, including stoppers, plungers, and delivery systems, which help ensure injectable medicines such as vaccines and biologics are safely stored and administered.
While we acknowledge the potential of WST as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 12 Best Income Stocks to Buy Now and 20 Best Performing Dividend Stocks in 2025
Disclosure: None.
